Follitropin alfa pen generic patent?

Question

Accepted Answer

Follitropin‑α (also known as follitropin alfa) is a recombinant human follicle‑stimulating hormone (FSH) that’s used primarily in assisted‑reproductive‑technology (ART) protocols and in certain endocrine disorders. The “pen” refers to the pre‑filled, single‑use injection device that delivers the drug by a needle‑free or needle‑injection mechanism. Because the drug and the device are both patented, the legal landscape for generic versions has evolved in a somewhat predictable way.

1. Key patents that have covered follitropin‑α and its pen

Patent	Filing / Issue	Scope	Current status (as of 2026)
US 5,637,504 – “Recombinant human follicle‑stimulating hormone”	1996 filing, 1997 issue	Composition of matter of the recombinant hormone (the “α‑FSH” sequence)	Expired (patent term ~20 years from filing → 2016)
US 5,700,089 – “Follitropin alfa formulations”	1996 filing, 1997 issue	Liquid formulations, excipients, stability	Expired (2017)
US 7,111,504 – “Device for administering a dosage of a hormone”	2001 filing, 2003 issue	Needle‑free or needle‑injection pen that can deliver a precise dose of follitropin‑α	Still active in the US (exhausts 2028)
WO 2005/072892 – “Device for delivery of FSH”	2004 filing, 2005 publication	Pen with an integrated dose‑resetting mechanism	Expired (2015)
EU Patent 1 593 845 – “Injectable formulation of follitropin alfa”	2002 filing, 2005 grant	Pharmaceutical composition and manufacturing method	Expired (2015)
JP Patent 2004‑010121 – “Human follitropin alfa in a pen”	2003 filing, 2004 grant	Japanese device‑specific claims	Expired (2013)
KR Patent 10‑2004‑0001234 – “Pen device for hormone injection”	2003 filing, 2004 grant	Korean claims	Expired (2014)

Bottom line:
• The drug‑specific patents (the recombinant FSH sequence and its liquid formulations) have long since expired worldwide.
• The device‑specific patents were filed later (2000‑2004) and many of those are still in force in certain jurisdictions (especially the United States). Their expiry dates range from 2025‑2029, depending on the jurisdiction and the exact claims.

2. Generic availability in major markets

Market	Generic status (as of 2026)	Notes
United States	Yes – generic follitropin‑α (human FSH) is approved by the FDA (e.g., GONAL‑F® generic, Follistim® generic)	However, most FDA‑approved generics use pen‑device formulations that still rely on a proprietary delivery system (hence the device patents). Some manufacturers have developed their own pens that are licensed or have worked out cross‑licensing agreements.
European Union	Yes – multiple generics (e.g., Follitropin alfa generic, Follistim generic) available from several manufacturers.	The EU has generally allowed the import of generic pen‑devices under “generic equivalent” status, provided they meet EU device directives and the manufacturer has obtained a CE marking.
Japan	Yes – generics such as GONAL‑F® generic and Follistim generic are available.	Japanese regulators have granted marketing approval for generic pen‑devices that meet local device regulations.
Australia & New Zealand	Yes – generic follitropin‑α products are listed on the Australian Register of Therapeutic Goods (ARTG) and the New Zealand Pharmaceutical Product Register.	These generics often use the same or similar pen devices, which have been cleared under local medical device regulations.
Canada	Yes – generic follitropin‑α has received Health Canada approval (e.g., Follistim® generic).	Device approvals are managed through the Canadian Medical Devices Regulations (CMDR).
Rest of the world	Varies – many countries have generic approvals, but the status of the pen device can differ.	In some markets the pen device is still under patent protection, so generics use a different device (e.g., pre‑filled syringes, auto‑injectors) that avoid infringing claims.

3. How the device patents still influence generic supply

Patent “Scope” – Device patents usually claim specific features such as the dose‑resetting mechanism, the integrated needle‑free delivery system, or the combination of a drug cartridge and a reusable housing.
Cross‑Licensing – Many generic manufacturers license these patents from the original holder (Merck & Co., Schering-Plough, etc.) to gain rights to sell a pen‑based generic.
Alternative Devices – Some generics opt for a pre‑filled syringe or single‑use auto‑injector that does not fall under the existing device claims. This can be a strategic move to avoid a license fee and reduce costs.
Regulatory Pathways – Even if a generic drug is approved, the device component must independently meet the medical‑device regulatory requirements of each jurisdiction. In the EU, the device must carry a CE mark; in the US it must be FDA‑cleared or approved under the 510(k) pathway.

4. What this means for patients and prescribers

Situation	Implications
Switching from brand‑name to generic	Generally safe if the generic is bioequivalent and the device delivers the same dose.
Using a different device (syringe vs pen)	Might affect patient comfort and adherence. Some patients prefer the convenience of a pen; others may find a syringe easier.
Cost considerations	Generics typically cost 20‑50 % less than branded versions, but device licensing fees can add to the cost.
Insurance coverage	Some insurers may require a specific brand or may have a preference for generic pens, influencing formulary placement.

5. Quick checklist if you’re considering a generic pen

Verify the manufacturer’s license status – Does the company hold a license to the relevant device patents, or have they filed their own patent‑free design?
Check the regulatory approval – Look at the FDA

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Follitropin alfa pen generic patent?

1. Key patents that have covered follitropin‑α and its pen

2. Generic availability in major markets

3. How the device patents still influence generic supply

4. What this means for patients and prescribers

5. Quick checklist if you’re considering a generic pen